Literature DB >> 6428844

Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.

R A DeFronzo, D C Simonson.   

Abstract

In the present paper we have reviewed the literature concerning the mechanisms of action of the oral sulfonylurea agents on glucose metabolism. In addition, we report our results examining the effect of glyburide in 10 non-insulin-dependent diabetic patients. Before therapy the fasting glucose concentration averaged 198 +/- 19 mg/dl and the oral glucose tolerance test (OGTT) was markedly abnormal. Following 3 mo of glyburide therapy, the fasting glucose had declined to 141 +/- 16 mg/dl (P less than 0.01 vs. preglyburide) and the OGTT (absolute plasma glucose concentration) was improved (P less than 0.001). However, the incremental increase (i.e., above basal) in plasma glucose during the OGTT was not significantly altered. In the postabsorptive state the fasting plasma glucose concentration is determined by only two factors: (1) the rate of glucose entry into the body, which is essentially equal to the rate of hepatic glucose production (HGP) and (2) the rate of glucose removal from the body or the glucose clearance. In the basal state HGP was slightly increased compared to age-matched controls and averaged 2.35 +/- 0.28 mg/kg X min. Following 3 mo of glyburide, HGP decreased to 1.72 +/- 0.18 mg/kg X min (P less than 0.01) and the decrease in HPG was strongly correlated with the decrease in fasting glucose (r = 0.85, P less than 0.005). Basal glucose clearance in non-insulin-dependent diabetes was reduced compared to controls (1.22 +/- 0.04 vs. 2.32 +/- 0.03 ml/kg X min, P less than 0.001) but did not change after glyburide (1.25 +/- 0.10).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428844

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation.

Authors:  N Frey; C Laveille; M Paraire; M Francillard; N H G Holford; Roeline Jochemsen
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

Review 2.  Oral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitus.

Authors:  Joanna Tieu; Suzette Coat; William Hague; Philippa Middleton
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

3.  Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets.

Authors:  D Gullo; A M Rabuazzo; M Vetri; C Gatta; C Vinci; M Buscema; R Vigneri; F Purrello
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

Review 4.  Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.

Authors:  Joanna Tieu; Suzette Coat; William Hague; Philippa Middleton; Emily Shepherd
Journal:  Cochrane Database Syst Rev       Date:  2017-10-18

5.  Molecular effects of sulphonylurea agents in circulating lymphocytes of patients with non-insulin-dependent diabetes mellitus.

Authors:  I Rabbone; M Piccinini; M Curto; M Mostert; S Gamba; S Mioletti; R Bruno; M T Rinaudo
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

6.  Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.

Authors:  S Del Prato; S Vigili de Kreutzenberg; A Riccio; L Maifreni; E Duner; G Lisato; M Iavicoli; A Tiengo
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

Review 7.  The use of oral antidiabetic medications in gestational diabetes mellitus.

Authors:  Michael J Paglia; Donald R Coustan
Journal:  Curr Diab Rep       Date:  2009-08       Impact factor: 4.810

8.  Plasma glucose lowering effect of sparteine sulphate infusion in non-insulin dependent (type 2) diabetic subjects.

Authors:  G Paolisso; S Sgambato; N Passariello; G Pizza; R Torella; P Tesauro; M Varricchio; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 9.  The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.

Authors:  Derek M Erion; Hyun-Jun Park; Hui-Young Lee
Journal:  BMB Rep       Date:  2016-03       Impact factor: 4.778

Review 10.  Natural products, an important resource for discovery of multitarget drugs and functional food for regulation of hepatic glucose metabolism.

Authors:  Jian Li; Haiyang Yu; Sijian Wang; Wei Wang; Qian Chen; Yanmin Ma; Yi Zhang; Tao Wang
Journal:  Drug Des Devel Ther       Date:  2018-01-10       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.